Digital X-Ray Market, Forecast to 2026-2033

Nucleic Acid Amplification Testing Market

Nucleic Acid Amplification Testing (NAAT) Market By Product Type (Reagents & Consumables, Instruments, Kits, Extraction Systems, Amplification Systems, Sample Preparation Products, Software, Others); By Technology (PCR, RT-PCR, Isothermal Amplification, LAMP, TMA, SDA, NASBA, Others); By Application (Infectious Disease Testing, Oncology Testing, Genetic Disease Testing, Respiratory Testing, STI Testing, Blood Screening, Food & Environmental Testing, Others); By End User (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Academic Institutions, Public Health Laboratories, Point-of-care Centers, Others); By Test Type (RNA Testing, DNA Testing, Multiplex Testing, Singleplex Testing, Quantitative Testing, Qualitative Testing, Screening Tests, Others)By Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2026-2033

Report ID : 3205 | Publisher ID : Transpire | Published : Sep 2026 | Pages : 259 | Format: PDF/EXCEL

Nucleic Acid Amplification Testing (NAAT) Market Summary:

As per Transpire Insight Analysis, the Nucleic Acid Amplification Testing (NAAT) Market size is estimated at USD 11.72 billion in 2025 and is anticipated to reach USD 23.90 billion by 2033, growing at a CAGR of 9.33% from 2026 to 2033.

The worldwide market for nucleic acid amplification tests is becoming an important tool for assisting in the quick diagnosis of diseases in hospitals, laboratories, primary care institutions, and decentralised testing units. In recent years, the market has undergone a trend of becoming more portable, automated, and point-of-care molecular testing tools, thereby decreasing the reliance on large central laboratories. This is further becoming a major driver for the market, owing to the fact that it increases the number of molecular tests and encourages healthcare systems to build their capacity for diagnosis. The market is now trending towards making NAATs available outside traditional laboratory settings. The World Health Organisation has made recommendations for the use of near-point-of-care NAATs for tuberculosis testing, which can be used in peripheral laboratories, primary care facilities, and communities.

Nucleic Acid Amplification Testing (NAAT) Market Size & Forecast:

  • Market Size 2025: USD 11.72 Billion
  • Expected Market Value (2033): USD 23.90 Billion
  • Forecast CAGR (2026–2033): 9.33%
  • Leading Region in 2025: North America
  • Fastest Growing Region: Asia Pacific
  • Key Company Profiles: Roche, Abbott, Thermo Fisher Scientific, Danaher, Hologic, Becton Dickinson, Bio-Rad, QIAGEN, bioMérieux, Cepheid, Seegene, Meridian Bioscience, Luminex, QuidelOrtho, Grifols

Key Market Insights:

The Nucleic Acid Amplification Testing (NAAT) Market is shifting towards rapid molecular testing and automation, where RNA testing constitutes the major share in terms of market segmentation provided. The oncology segment is emerging as one of the fastest-growing applications, with the growing significance of molecular diagnostics in oncology.

  • RNA Testing accounted for 54% of the market, as laboratories increasingly rely on RNA-based molecular tests for detecting infectious diseases and other applications.
  • DNA Testing accounted for 17%, as laboratories continue to rely on molecular tests for genetic disorders, pathogens, and disease-related biomarkers.
  • Multiplex Testing accounted for 10%, due to the trend towards molecular tests that can detect several targets from one patient sample and increase laboratory efficiency.
  • Singleplex Testing accounted for 7%, as there is still a demand for molecular testing of an individual target when it is required in laboratories.
  • Quantitative Testing accounted for 5%, thanks to the applications where the amount of nucleic acids is important for disease diagnosis and treatment.
  • Qualitative Testing accounted for 4%, as there is still a need for a simple positive or negative test result in diagnostics.
  • Other tests accounted for only 1%, while novel molecular platforms and decentralised testing methods keep on widening the scope of NAATs usage.

What are the Key Drivers, Restraints, and Opportunities in the Nucleic Acid Amplification Testing (NAAT) Market?

Drivers

The increasing burden of infectious diseases is acting as one of the key drivers of the Nucleic Acid Amplification Testing (NAAT) Market. There has been a growing demand for fast and sensitive technology that would diagnose infectious diseases and assist in clinical decision-making. The development of molecular diagnostics, automation, and point-of-care testing has made it easier to use NAAT in hospitals and laboratories.

Restraints

 High costs associated with instruments, regulatory issues, and trained personnel still restrain the use of NAAT technology. The above factors increase implementation costs and delay the process of replacing traditional diagnostic techniques.

Opportunities

The most significant opportunity for NAAT lies in its integration with portability, automation, multiplexing, and isothermal platforms. The systems can speed up the process while relying less on centralised laboratories. In addition, oncology offers great expansion opportunities due to the increasing use of molecular testing for oncology biomarker testing.

What Has the Impact of Artificial Intelligence Been on the Nucleic Acid Amplification Testing (NAAT) Market?

AI technology is useful in improving the processing, interpretation, and management of nucleic acid amplification tests. AI algorithms that can be used in molecular diagnostics include the capacity to process signals from amplification reactions and images, eliminate background signals, classify reactions, and improve the interpretation of the tests in question. AI-assisted digital NAAT research reveals the benefits of digital NAAT in enhancing image analysis, quantitative detection, and point-of-care testing.AI is assisting in the prediction of emerging molecular diagnostic platforms such as target and guide design, signal interpretation, and improvement in testing workflow. Seegene developed CURECA, an unattended PCR automation platform, and STAgora, a data analytics platform, to enhance automated testing and infectious disease monitoring. Challenges exist when it comes to the implementation of AI technology. Implementation of AI technologies in existing laboratory systems may require heavy investment, validation, and regulation, while variations in clinical samples and testing environments may impact algorithm performance.

Instance

In May 2025,Diagnostics.ai developed its AI platform certified under the CE-IVDR for clinical real-time PCR diagnostics, which makes it possible to perform PCR result analysis, quality control and traceability automatically. The example shows how AI technology is being incorporated into molecular testing workflows.

https://www.diagnostics.ai/

Key Market Trends:

The Nucleic Acid Amplification Testing (NAAT) Market is evolving towards more rapid, decentralised, and automated molecular diagnostics. New technologies are driving NAAT from conventional lab-based procedures to more advanced point-of-care testing, multiplex testing, oncology, and digital-based diagnostics.

  • Adoption of point-of-care NAAT has grown as molecular testing has moved away from centralised laboratories towards more patient-oriented and decentralised solutions.
  • Isothermal amplification technologies have gained traction due to the lack of conventional thermal cycling required for such techniques as LAMP and similar methods.
  • Multiplex testing has gained importance due to the possibility of detecting several pathogens using one workflow, which is very helpful for diagnosing respiratory diseases.
  • Sample-to-answer systems have been evolving, and now they can cover both sample preparation, amplification and results interpretation in one integrated system.
  • Applications of NAAT have expanded to the oncology field, and molecular testing has become an important tool for detecting circulating tumour DNA, identifying biomarkers and providing precise treatment.
  • AI-powered molecular diagnostics have emerged, especially in relation to automated results interpretation.

Nucleic Acid Amplification Testing (NAAT) Market Segmentation

By Product Type

The Nucleic Acid Amplification Testing (NAAT) Market comprises reagents and consumables, instruments, kits, extraction systems, amplification systems, sample preparation products, software, and other supporting products. The category of reagents and consumables will continue to be commercially significant because NAAT requires recurring purchases of consumables after setting up the instrument. Companies are now working on integrated consumables, automated sample preparation, and cartridge format.

By Technology

the market consists of PCR, RT-PCR, isothermal amplification, LAMP, TMA, SDA, NASBA, and other forms of amplification. PCR remains dominant due to its clinical significance, high accuracy, and large number of assays available, whereas the advent of isothermal methods has provided opportunities for rapid testing in areas where conventional thermal-cycling machines cannot be used.

By Application

 the market includes infectious disease testing, oncology testing, genetic disease testing, respiratory testing, STI testing, blood testing, food & environmental testing, and other applications. Amongst these, infectious disease testing continues to be an important application, whereas the fastest-growing application segment is that of oncology testing, growing at an 11.40% CAGR due to the rise in the adoption of molecular testing for cancer biomarkers and mutations.

By End Users

From hospitals, laboratories for diagnosis, research laboratories, pharmaceuticals, educational institutions, public health laboratories, point-of-care laboratories, and other health care establishments. Reference and diagnostic laboratories play an important role because they are dealing with high-volume testing and complicated molecular processes, whereas hospitals and point-of-care laboratories are becoming more important with increasing testing nearer to the patient population. Increased usage of decentralised platforms will provide more opportunities for NAAT vendors

By Test Type

RNA Testing holds the top market share position with 54%, trailed by DNA Testing with 17%, Multiplex Testing with 10%, Singleplex Testing with 7%, Quantitative Testing with 5%, Qualitative Testing with 4%, Screening Tests with 2%, and Others with 1%. RNA Testing maintains its dominance in the market owing to its extensive use in diagnostic tests for viruses and other molecules, while Multiplex Testing is being emphasized on account of its capability to identify multiple targets in a single sample.

What are the Key Use Cases Driving the Nucleic Acid Amplification Testing (NAAT) Market?

Infectious disease testing is a use case of NAAT. Rapid identification and sensitive detection of the pathogen may affect treatment and infection control. The NAAT technology is commonly applied in testing viral infections, bacterial and other microorganisms that might be challenging to diagnose using conventional culture tests. Another area of testing by NAAT is respiratory test where the molecular testing technology assists in the diagnosis of respiratory viruses and thus allows faster decision-making. The multiplex respiratory panels have extended the number of pathogens that can be detected from one specimen. New use cases in oncology and decentralised testing will drive the growth in adoption of NAAT. Molecular amplification techniques are increasingly being used for cancer markers. The portable NAAT technology has improved testing in locations without laboratory facilities.

Report Metrics

Details

Market size value in 2025

USD 11.72 Billion

Market size value in 2026

USD 12.80 Billion

Revenue forecast in 2033

USD 23.90 Billion

Growth rate

CAGR of 9.33% from 2026 to 2033

Base year

2025

Historical data

2021 - 2024

Forecast period

2026 - 2033

Report coverage

Revenue forecast, competitive landscape, growth factors, and trends

Regional scope

United States; Canada; Mexico; United Kingdom; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; United Arab Emirates

Key company profiled

Roche, Abbott, Thermo Fisher Scientific, Danaher, Hologic, Becton Dickinson, Bio-Rad, QIAGEN, bioMérieux, Cepheid, Seegene, Meridian Bioscience, Luminex, QuidelOrtho, Grifols

Customization scope

Free report customization (country, regional & segment scope). Avail customized purchase options to meet your exact research needs.

Report Segmentation

By Product Type (Reagents & Consumables, Instruments, Kits, Extraction Systems, Amplification Systems, Sample Preparation Products, Software, Others); By Technology (PCR, RT-PCR, Isothermal Amplification, LAMP, TMA, SDA, NASBA, Others); By Application (Infectious Disease Testing, Oncology Testing, Genetic Disease Testing, Respiratory Testing, STI Testing, Blood Screening, Food & Environmental Testing, Others); By End User (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Academic Institutions, Public Health Laboratories, Point-of-care Centers, Others); By Test Type (RNA Testing, DNA Testing, Multiplex Testing, Singleplex Testing, Quantitative Testing, Qualitative Testing, Screening Tests, Others)

Which Regions are Driving the Nucleic Acid Amplification Testing (NAAT) Market Growth?

North America

North America is the dominant regional market with a market share of 36% in the Nucleic Acid Amplification Testing (NAAT) Market. This regional dominance is driven by efficient laboratory setups, high expenditure on health care and extensive use of molecular diagnostics among hospitals and diagnostic centres. Research capacities and the established presence of diagnostic companies in the region also contribute to the region's leadership position in the NAAT market.

In June 2026, Autonomous Medical Devices Inc. received clearance from the U.S. FDA and was waived from CLIA for its Fast PCR System and Mini Respiratory Panel, which enables rapid molecular diagnosis of respiratory illnesses in decentralized healthcare settings.

https://www.prnewswire.com/news-releases/amdi-fast-pcr-system-receives-fda-510k-clearance-and-clia-waiver-for-sub-10-minute-respiratory-panel-302801243.html

Europe

Europe is the second largest regional market with a market share of 29%. It is driven by an efficient health care system, developed laboratory networks, a regulatory framework for molecular diagnostic products and continued demand in the fields of infectious disease surveillance and genetic diagnostics, in addition to the increasing use of molecular diagnostics in cancer detection. Germany and other major European markets are investing in automated and high-throughput testing technologies which drive regional growth in the NAAT market.

In July 2026, QIAGEN introduced the QIAstat-Dx BCID GN Plus AMR Panel to the European market following CE-IVDR approval. This multianalyte molecular assay allows for detection of 13 gram-negative bacterial pathogens and 18 antimicrobial resistance markers derived from positive blood cultures within one hour.

https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Expands-QIAstat-Dx-Bloodstream-Infection-Testing-Menu-in-Europe/default.aspx

Asia Pacific

The Asia-Pacific region is 20% of the market and has the highest rate of growth with 10.66% CAGR. This growth is driven by improved health care facilities, investments by governments in molecular diagnostics and expanded use of NAAT in countries like China and India. There are many possibilities for decentralisation of molecular diagnostics in the region.

In April 2025, Cepheid announced the increasing use of its GeneXpert molecular diagnostics platform in India, where there are more than 20 tests available on the platform, out of which CBNAAT is one. The platform allows decentralised molecular testing by performing rapid testing in hospitals and laboratories of the region.

https://www.cepheid.com/pl-PL/campaigns/india/cepheid-india.html

Who are the Key Players in the Nucleic Acid Amplification Testing (NAAT) Market and how do they compete?

By Product Type

  • Reagents & Consumables
  • Instruments
  • Kits
  • Extraction Systems,
  • Amplification Systems
  • Sample Preparation Products
  • Software

By Technology

  • PCR
  • RT-PCR
  • Isothermal Amplification
  • LAMP
  • TMA
  • SDA
  • NASBA

By Application

  • Infectious Disease Testing
  • Oncology Testing
  • Genetic Disease Testing
  • Respiratory Testing
  • STI Testing
  • Blood Screening
  • Food & Environmental Testing

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical Companies
  • Academic Institutions
  • Public Health Laboratories
  • Point-of-care Centers

By Test Type

  • RNA Testing
  • DNA Testing
  • Multiplex Testing
  • Singleplex Testing
  • Quantitative Testing
  • Qualitative Testing
  • Screening Tests

Frequently Asked Questions

Find quick answers to common questions.

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Abbott
  • Qiagen N.V.
  • Biomerieux
  • Danaher Corporation
  • Hologic Inc.
  • Agilent Technologies
  • Illumina
  • BGI Genomix,
  • Mylab
  • Molbio Diagnostics
  • Seegene Inc.
  • Diasorin
  • Meridian Bioscience

About the Authors

Pankaj Ghogare Patil -Author TI

Pankaj Ghogare Patil

I am Pankaj Ghogare Patil, a Senior Research Analyst at Transpire Insight, specializing in the Pharmaceutical, Chemicals & Materials, Healthcare IT, and Biotechnology industry. My expertise lies in conducting comprehensive market research, analyzing industry trends, evaluating competitive landscapes, and translating complex data into actionable insights. At Transpire Insight, I closely follow emerging technologies, regulatory developments, and market innovations to create accurate, well-researched, and informative content that helps businesses and professionals make informed decisions. I am committed to producing credible, evidence-based articles that reflect industry best practices while making technical topics accessible and valuable for a broad audience.

Chakradhar Khansole -Author TI

Chakradhar Khansole

Chakradhar serves as the Research Director at Transpire Insight, bringing over 8 years of experience in technology, innovation, and strategic market intelligence. He specializes in transforming complex market data into actionable business insights that enable organizations to make informed, growth-oriented decisions. Recognized for his strategic vision and analytical expertise, Chakradhar leads high-impact research initiatives, delivering comprehensive market assessments, competitive intelligence, and forward-looking industry analysis.

Recently Published Reports